Arcellx To Present Clinical Data for Phase 1 And IMMagine-1 Studies At 66th ASH Annual Meeting; Median Not Reached For Phase 1 Study Of Anito-cel
Arcellx To Present Clinical Data for Phase 1 And IMMagine-1 Studies At 66th ASH Annual Meeting; Median Not Reached For Phase 1 Study Of Anito-cel
-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached --
-- 在阿尼託賽爾1期研究中，隨訪時長中位數爲38.1個月，中位無進展生存時間爲30.2個月；總體生存時間中位數尚未達到 --
-- Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation --
-- iMMagine-1關鍵性2期研究中58名接受者的初步結果顯示，隨訪時長中位數爲10.3個月，ORR爲95%，CR/sCR爲62%；具有更近期數據切點的額外接受者將在口頭報告中呈現 --
-- No delayed neurotoxicities have been observed to date with anito-cel, including no parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome across the Phase 1 and iMMagine-1 studies in the more than 140 patients dosed --
-- 在阿尼託賽爾中尚未觀察到遲發性神經毒性，包括沒有帕金森症、無顱神經麻痹和無吉蘭-巴雷綜合徵，在超過140名接受者中，跨1期和iMMagine-1研究 --
-- First patient dosed in iMMagine-3 study, manufactured by Kite; turnaround time in line with Kite's commercial products --
-- iMMagine-3研究中首名接受者的投藥，由凱特生產；週轉時間與凱特的商業產品一致 --
-- Company to host a live webcast event with an expert panel of clinicians on Monday, December 9, 2024 at 8:30 p.m. --
-- 公司將於2024年12月9日星期一晚上8:30舉辦一場現場網絡研討會，由專家臨床團隊主持 --
